Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 3:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 673 matching trials from the live ClinicalTrials.gov search.
Conditions
Migraine
Interventions
Eucalyptus Oil Scent, Isopropyl Alcohol Vapors
Other
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Scottsdale, Arizona
Completed Phase 2 Interventional Results available

Treatment for Migraine and Mood (Team-M)

NCT04992494
Conditions
Migraine, Depression
Interventions
MBCT-Telephone, MBCT-Video
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Completed Phase 2 Interventional Results available

A Study of LY3451838 in Participants With Migraine

NCT04498910
Conditions
Migraine
Interventions
LY3451838, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
9
States / cities
Phoenix, Arizona • Stamford, Connecticut • Ocala, Florida + 6 more
Conditions
Migraine, Migraine in Adolescence
Interventions
BREATHE with Headache (BREATHE-HA), Enhanced Standard-of-Care: Headache Education
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 17 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Migraine, Major Depressive Disorder
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
17
States / cities
Little Rock, Arkansas • San Diego, California • Denver, Colorado + 14 more
Conditions
Migraine
Interventions
Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Migraine
Interventions
DFN-15 Dose A (treatment A), DFN-15 Dose B (treatment B), Placebo (treatment C)
Drug · Other
Lead sponsor
Dr. Reddy's Laboratories Limited, India
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Long Beach, California • Santa Monica, California • Watertown, Massachusetts + 3 more
Conditions
Migraine
Interventions
lasmiditan 200 mg
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Orlando, Florida • Knoxville, Kentucky
Conditions
Migraine Headache
Interventions
Argus Migraine Treatment device
Device
Lead sponsor
The San Francisco Clinical Research Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Francisco, California
Conditions
Migraine
Interventions
BHV-2100, Placebo
Drug
Lead sponsor
Biohaven Therapeutics Ltd.
Industry
Eligibility
18 Years to 64 Years
Enrollment
647 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
60
States / cities
Gilbert, Arizona • Encino, California • Los Alamitos, California + 57 more
Completed No phase listed Observational Accepts healthy volunteers

Migraine and Body Composition

NCT01720862
Conditions
Migraine With and Without Aura, Chronic Migraine, Healthy Controls
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Migraine
Interventions
Nerivio REN device
Device
Lead sponsor
Theranica
Industry
Eligibility
8 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Migraine
Interventions
Daily questionnaire
Other
Lead sponsor
Theranica
Industry
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2030
U.S. locations
3
States / cities
Westport, Connecticut • Ridgeland, Mississippi • Poughkeepsie, New York
Conditions
Migraine Disorders
Interventions
NP101
Drug
Lead sponsor
NuPathe Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Newport Beach, California + 31 more
Conditions
Migraine
Interventions
CVT-427 (zolmitriptan inhalation powder)
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
3
States / cities
North Dartmouth, Massachusetts • Lincoln, Nebraska • Dallas, Texas
Conditions
Migraine
Interventions
Lasmiditan
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
6 Years to 17 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
Scottsdale, Arizona • Newport Beach, California • Stamford, Connecticut + 5 more
Conditions
Migraine
Interventions
Atogepant 60 mg, Propranolol 160 mg, Topiramate 100 mg
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
1,335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
39
States / cities
Hazel Green, Alabama • Flagstaff, Arizona • Phoenix, Arizona + 32 more
Terminated Phase 2 Interventional Accepts healthy volunteers

Intranasal Ketorolac Trial

NCT06083571
Conditions
Headache, Migraine
Interventions
Ketorolac, Prochlorperazine, Diphenhydramine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
6 Years to 17 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Completed Not applicable Interventional Accepts healthy volunteers

MRI Outcomes of Mindfulness Meditation for Migraine

NCT02133209
Conditions
Migraine
Interventions
Mindfulness Based Stress Reduction, Stress Management for Headaches
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
2
States / cities
Baltimore, Maryland
Conditions
Migraine, Migraine Disease, Migraine in Adults, Migraine Headache, Acute Migraine, Migraine Without Aura, Migraine With Aura
Interventions
Rimegepant, Zavegepant
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Migraine, Tension-type Headache, Primary Headache Disorder
Interventions
Sumatriptan 100 mg, Naproxen
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Conditions
Migraine
Interventions
Aimovig
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,839 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Migraine
Interventions
duloxetine
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Prospective Survey of Menstrual Migraine & Prevention With Eletriptan

NCT00259649
Conditions
Migraine
Interventions
eletriptan
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2004
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania